Form 4: Humana Executive Reports Stock Transactions
Insider Transaction Report
Humana's President of CenterWell, Sanjay K. Shetty, reported the acquisition and disposal of common stock related to equity awards and tax obligations.
Summary
- Sanjay K. Shetty, President, CenterWell at Humana Inc., reported transactions on December 15, 2025, under a Rule 10b5-1 plan.
- Acquired a total of 2,276 shares of Humana Common stock (1,968 shares and 308 shares) at a price of $0, likely through the exercise of options or vesting of restricted stock units.
- Disposed of a total of 1,027 shares of Humana Common stock (888 shares and 139 shares) at a price of $270.155 per share to satisfy tax withholding obligations related to the equity awards.
- Following these transactions, Shetty's direct beneficial ownership of Humana Common stock is 10,847 shares, which includes 8,818 restricted stock units.
Sentiment
Score: 5
Explanation: The filing details routine insider transactions related to equity compensation, which are generally neutral in sentiment as they are pre-scheduled and expected.
Positives
- The acquisition of 2,276 shares of Humana Common stock at a $0 price indicates the vesting or exercise of equity compensation, aligning executive incentives with shareholder value.
- The transactions were conducted under a Rule 10b5-1 plan, demonstrating pre-planned and transparent insider trading activity.
- Sanjay K. Shetty maintains a significant direct beneficial ownership of 10,847 shares, including 8,818 restricted stock units, indicating continued alignment with the company's long-term performance.
Negatives
- The disposal of 1,027 shares of Humana Common stock at $270.155 per share, while for tax purposes, reduces the executive's direct shareholding.
Future Outlook
NA
Industry Context
NA
Next Steps
- Remaining tranches of options granted on April 1, 2023, will vest in annual increments until April 1, 2026.
- Remaining tranches of options granted on February 21, 2024, will vest in annual increments until February 21, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/01/2023 | Grant date for options with an exercise price of $487.1602 and Restricted Stock Units. |
| 12/15/2023 | Vesting date for 33% of Restricted Stock Units granted on 4/1/2023. |
| 02/21/2024 | Grant date for options with an exercise price of $367.21. |
| 04/01/2024 | First annual vesting increment for options granted on 4/1/2023. |
| 12/15/2024 | Vesting date for 33% of Restricted Stock Units granted on 4/1/2023. |
| 02/21/2025 | First annual vesting increment for options granted on 2/21/2024. |
| 12/15/2025 | Transaction date for stock acquisitions and disposals; final vesting date for 33% of Restricted Stock Units granted on 4/1/2023. |
| 12/17/2025 | Signature date of the reporting person. |
| 04/01/2026 | Final annual vesting increment for options granted on 4/1/2023. |
| 02/21/2027 | Final annual vesting increment for options granted on 2/21/2024. |
| 04/01/2030 | Expiration date for options granted on 4/1/2023. |
| 02/21/2031 | Expiration date for options granted on 2/21/2024. |
Recommendation
holdThe Form 4 filing details routine insider transactions related to equity compensation, including the exercise of options/vesting of restricted stock units and subsequent sale of shares to cover tax obligations. These transactions were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new material non-public information. As such, this filing does not provide new fundamental information to alter an investment thesis, warranting a 'hold' recommendation.
Keywords
Humana, HUM, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Executive Compensation, Rule 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.